MDS Analytical Technologies has announced that its Spectramax L microplate luminometers have received Dual-Luciferase Reporter Assay (DLReady or DLR) certification from Promega Corporation.
The certification confirms that Spectramax L microplate luminometers meet Promega's performance criteria for the Dual-Luciferase Reporter Assay.
Andy Boorn, president of MDS Analytical Technologies, said: 'DLReady certification by Promega provides our mutual customers with greater assurance of excellent performance for this highly sensitive, accurate and rapid assay on the Spectramax L microplate luminometer.
'DLR certification extends to the entire family of Spectramax L readers, including our multiple-detector-based luminometer released earlier this year,' he added.
The Dual-Luciferase Reporter Assay is widely used to study gene transcription and regulation.
This dual-reporter assay enables normalisation of the activity of an experimental reporter to the activity of an internal control, minimising experimental variability caused by differences in cell viability or transfection efficiency.
The activities of two enzymes - Firefly luciferase and Renilla luciferase - are measured sequentially from a single sample.
DLR-certified luminometers undergo an extensive validation process to help users obtain the best possible performance with the Dual-Luciferase Reporter Assay.
Kevin Kopish, global product manager for cellular analysis at Promega Corporation, said: 'Promega has tested and certified that the Spectramax L microplate luminometer meets our criteria for performance with the Dual-Luciferase Reporter Assay.
'The DLReady programme ensures that customers can have confidence in their scientific results and not worry about reagent or instrument performance,' he added.
MDS Analytical Technologies is a supplier of drug-discovery and life-sciences research tools, while Promega Corporation is a provider of solutions and technical support to the life-sciences industry.
